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Hepatitis B virus (HBV), a major cause of liver disease, has infected approximately 2 billion people worldwide, and more than 350 million are chronically infected \[[@b1-cmh-2016-0108]\]. Persistent viral replication increases the risk of progression to liver cirrhosis, development of hepatocellular carcinoma (HCC) and liver-related death \[[@b2-cmh-2016-0108]-[@b4-cmh-2016-0108]\]. Therefore, the goals of antiviral therapy are to improve quality of life and survival by preventing progression of the disease to cirrhosis, HCC and death \[[@b5-cmh-2016-0108],[@b6-cmh-2016-0108]\]. These goals can be achieved if HBV replication can be suppressed completely. Recent clinical studies showed that long-term suppression of HBV replication using anti-viral agents in patients with CHB can prevent progression to liver cirrhosis, hepatic failure and the development of HCC \[[@b2-cmh-2016-0108]-[@b5-cmh-2016-0108],[@b7-cmh-2016-0108]-[@b9-cmh-2016-0108]\].

Lamivudine (LAM), adefovir dipivoxil (ADV), telbivudine (Ltd), entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are available nucleos(t)ide analogues (NAs) for treating CHB patients worldwide. However, long-term treatment with NAs other than ETV and TDF increase the risk of drug resistance up to 80% because of low antiviral efficacy and low genetic barrier \[[@b10-cmh-2016-0108]-[@b14-cmh-2016-0108]\], Therefore, most guidelines recommend peg-interferon, ETV, or TDF in treatment-naïve patients \[[@b5-cmh-2016-0108],[@b15-cmh-2016-0108]\].

ADV add-on therapy has been widely used as a rescue therapy for patients with LAM-resistant CHB before TDF was not available \[[@b6-cmh-2016-0108],[@b16-cmh-2016-0108]\]. However, suboptimal response has been commonly observed in patients receiving ADV-based therapy \[[@b17-cmh-2016-0108]-[@b19-cmh-2016-0108]\].

TDF, one of very potent antiviral agent with a high genetic barrier, showed excellent virologic response (VR), defined as serum HBV DNA level undetectably by sensitive PCR method, in NAs-naïve \[[@b20-cmh-2016-0108],[@b21-cmh-2016-0108]\] and NAs-resistant patients \[[@b22-cmh-2016-0108]-[@b26-cmh-2016-0108]\]. Clinical efficacies of TDF therapy in NA-naïve and experienced patients are summarized in [Table 1](#t1-cmh-2016-0108){ref-type="table"}. In NA naïve patients, a significantly higher proportion of patients receiving TDF than of those receiving ADV had reached VR at 48 weeks ([Table 1](#t1-cmh-2016-0108){ref-type="table"}). Almost all patients who received TDF therapy showed VR without any evidence of resistance at seven year \[[@b14-cmh-2016-0108]\]. In patients with LAM-resistant patients receiving TDF or TDF/emtricitabine (FTC), VR achieved in 89.4% and 86.3% at 96 weeks of therapy, respectively \[[@b24-cmh-2016-0108]\], without any evidence of TDF resistance during 5 years of follow-up \[[@b27-cmh-2016-0108]\]. TDF also showed high rate of VR in patients with ETV resistance \[[@b26-cmh-2016-0108]\]. In a randomized controlled trial conducted by Lim et al. \[[@b26-cmh-2016-0108]\] the proportion of patients with HBV DNA \<15 IU/mL was high in patients who received TDF and TDF+ETV groups (71% vs. 73%; *P*=0.99). In patients with ADV-resistant patients with prior LAM resistance, the proportion of patients with HBV DNA \<15 IU/mL was not significantly different between the TDF-TDF and TDF/ETV-TDF groups at weeks 48 (62% vs. 63.5%; *P*=0.88) and 96 (64% vs. 63.5%; *P*=0.96), suggesting that TDF monotherapy or combination therapy is effective even in patients with NAs-resistant patients.

There are several studies to evaluate the antiviral efficacy of TDF monotherapy or combination in patients with suboptimal response to ADV with or without prior resistance to LAM \[[@b23-cmh-2016-0108],[@b28-cmh-2016-0108],[@b29-cmh-2016-0108]\]. Berg, et al. conducted a randomized controlled trial to compare the anti-viral efficacy of TDF-based therapy for patients with CHB who had a suboptimal response to ADV (73% of the patients had received prior LAM therapy). A TDF monotherapy and TDF+FTC combination therapy showed similar VR at 48 week (81% vs. 81%) \[[@b23-cmh-2016-0108]\]. Cho et al. reported that the rate of VR was about 86.5 % through TDF monotherapy or TDF-based combination therapy in CHB patients with suboptimal responses to ADV plus LAM combination therapy \[[@b28-cmh-2016-0108]\]. Park et al. reported that the rate of VR was significantly higher in patients receiving TDV+ETV than in those receiving ADV+ETV for 12 months (84.8% vs. 26.7%, *P*\<0.001) \[[@b29-cmh-2016-0108]\]. However, little randomized controlled trials are available to compare between to switch into TDF-based therapy or to continue ADV-based therapy in CHB patients with suboptimal response to ADV-based therapy.

In the current issue, Lee et al. \[[@b30-cmh-2016-0108]\] conducted a randomized controlled trial to compare the antiviral efficacy comparing between switching to TDF+NAs therapy and continuing current ADV+NA therapy in patients with suboptimal response to ADV-based therapy. They clearly showed that TDF+NAs therapy provide better VR compared to continue ADV+ NA who showed suboptimal response to ADV-based therapy (87.5% vs. 37.5% at 48 weeks, *P*=0.002).

However, there are several limitations of the study. First, even though the study was designed as a randomized controlled trial, the sample size was very small to conclude the results. Second, in this study, there was no TDF monotherapy group because TDF monotherapy and TDF+NAs combination therapy did not show any difference in VR in NA-experienced patients ([Table 1](#t1-cmh-2016-0108){ref-type="table"}). In addition, Yang et al. \[[@b31-cmh-2016-0108]\] compared the antiviral efficacy between switching to TDF monotherapy and continuing ADV+LAM combination therapy in patients with suboptimal response to ADV+LAM (prior LAM resistance patients) therapy. TDF monotherapy showed higher VR compared with continuing ADV+LAM combination therapy (96.43% vs. 29.0%; *P*\<0.001). ADV monotherapy in patients with LAM resistance increase the risk of drug resistance \[[@b17-cmh-2016-0108]-[@b19-cmh-2016-0108]\]. Therefore, there is a concern about selective pressure on pre-existing resistant mutant viruses \[[@b32-cmh-2016-0108]\]. However, clonal analysis revealed that there is no significant selective pressure on pre-existing ADV or LAM resistant strains in during NA monotherpay patients with CHB and suboptimal response to ADV therapy who receiving TDF or TDF+FTC combination therapy \[[@b33-cmh-2016-0108]\].

In conclusion, considering the result from current study \[[@b30-cmh-2016-0108]\] and previous studies \[[@b23-cmh-2016-0108]-[@b26-cmh-2016-0108],[@b31-cmh-2016-0108]\], TDF with or without NAs might be very effective to treat the patient with suboptimal response to ADV-based therapy.
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Summary of randomized controlled trials to evaluate the anti-viral efficacy of tenofovir-based therapy in patients with NAs-naïve or experienced patients

  Authors                                            Study populations                                                                                                                Intervention                                Primary efficacy end point             Virologic response
  -------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- -------------------------------------- -----------------------------------
  Marcellin et al. (2008) \[[@b20-cmh-2016-0108]\]   NAs-naïve                                                                                                                        TDF vs. ADV                                 HBV DNA level \<69 IU/mL at 48 week    76% vs. 13% in HBeAg (+) patients
  HBeAg (+) (n=266)                                  96.8% vs. 71.2% in HBeAg (-) patients                                                                                                                                                                               
  HBeAg (-) (n=375)                                                                                                                                                                                                                                                      
  Fung et al. (2014) \[[@b24-cmh-2016-0108]\]        LAM -resistant                                                                                                                   TDF (n=141) vs. TDF/FTC (n=139)             HBV DNA level \<69 IU/mL at 96 week    89.4% vs. 86.3 % (*P*=0.43)
  Lim et al. (2016) \[[@b25-cmh-2016-0108]\]         ADV-resistant (100% LAM-resistant)                                                                                               TDF (n=50) vs. TDF/ETV (n=52)               HBV DNA level \<15 IU/mL at 48 week    62% vs. 63.5% (*P*=0.88)
  Lim et al. (2016) \[[@b26-cmh-2016-0108]\]         ETV-resistant                                                                                                                    TDF (n=45) vs. TDF/ETV (n=5)                HBV DNA level \<15 IU/mL at 48 week    71% vs. 73% (*P*=0.99)
  Berg et al. (2010) \[[@b23-cmh-2016-0108]\]        Suboptimal response to ADV (73% of the patients had received prior LAM therapy)                                                  TDF (n=53) vs. TDF/FTC (n=52)               HBV DNA level \<69 IU/mL at 48 week    81% vs. 81% (*P*=ns)
  Yang et al. (2015) \[[@b31-cmh-2016-0108]\]        Suboptimal response to ADV/LAM (prior LAM resistance patients)                                                                   TDF (n=28) vs. continue ADV/LAM (n=31)      HBV DNA level \<200 IU/mL at 48 week   96.43% vs. 29.0% (*P*\<0.001)
  Lee et al. (2016) \[[@b30-cmh-2016-0108]\]         Suboptimal response to ADV-based combination therapy due to NA resistance (LAM-resistant 9, Ldt-resistant 14, ETV-resistant 9)   TDF +NA (n=16) vs. continue ADV+NA (n=16)   HBV DNA level \< 60 IU/mL at 48 week   81.3% vs. 56.3% (*P*\<0.001)

ADV, adefovir dipivoxil; ETV, entecavir; TDF, tenofovir disoproxil fumarate; TDF/FTC, TDF/emtricitabine; LAM, lamivudine; NAs, nucleos(t)ide analogues.
